MUC1

Product List

Creative Biolabs provides various Anti-MUC1-related products to support global customers’ projects, please feel free to contact us for further communication.

Background

MUC1 is a glycoprotein with extensive O-linked glycosylation of its extracellular domain. It is overexpressed in a variety of epithelial cancers and plays a crucial role in the progression of the disease. Tumor-associated MUC1 differs from the MUC1 expressed in normal cells with regard to its biochemical features, cellular distribution, and function. Based on these features of MUC1 between normal and tumor cells, MUC1 has been investigated as one of the hot targets for antibody and engineering CAR T cells for cancer therapy.

Fig.1 Schematic representation of the recognition of different domains by different antibodies.¹

Associated Disease

Lung cancer

Pancreas cancer

Breast cancer

MUC1-expressing tumors

Viral infection

Others

Anti-MUC1 CAR-T Services

Anti-MUC1 CAR-T In Vitro Assays

Anti-MUC1 CAR-T Expression Test

For CART research, Creative Biolabs is dedicated to providing several innovative CAR detection reagents for CAR expression validation. Meanwhile, we also provide a comprehensive range of assay services to support your CART projects. For example, validation of anti-MUC1 CAR expression by flow cytometry is usually a classical assay format in MUC1 CAR therapy projects, providing a lot of intuitive information to clients.

Fig.2 Anti-MUC1 CAR expression evaluation in transduced human T cells by FACS analysis of Myc-tag expression. Anti-MUC1 CAR cells were gated by CD4 or CD8 channel, and then detected Myc-tag expression.²

Anti-MUC1 CAR-T Cytokine Release Test

The cytokine release test is a valuable assay in CART validation and characterization, which provides valuable insights into the activated and lytic phenotype of CAR T cells. Common types of cytokine tests include IFN-γ, TNF-α, IL-2, Granzyme B, along with many other cytokines. Creative Biolabs specializes in providing comprehensive cytokine release test services for global clients by many approaches, including ELISA, CBA, and FACS staining intracellularly.

Fig.3 IFN-γ and Granzyme B secretion detection of anti-MUC1 CAR-T cells co-cultured with tMUC1high HCC70 cells by FACS staining intracellularly for IFN-γ and Granzyme B.²

Fig.4 Cytokines panel detection of anti-MUC1 CAR-T cells co-cultured with tMUC1high HCC70 cells at E:T ratio of 2:1 by human cytokine array.²

Anti-MUC1 CAR-T In Vitro Cytotoxicity Assay

CAR T cell-mediated tumor-killing test is an important indicator for CART research. Creative Biolabs offers in vitro cytotoxicity assay services to support the evaluation of anti-MUC1 CAR-T cell therapy by various approaches, such as radioactive chromium release method, bioluminescence method, and flow cytometry method. In the testing service, we will optimize the experimental conditions according to customers' special needs to get more desirable data results.

Fig.5 In vitro cytotoxicity activity of anti-MUC1 CAR-T cells against TNBC tumor cells. (A) tMUC1 expression validation of several TNBC cell lines by flow cytometry. (B) In vitro cytotoxicity validation of MUC1 CAR T cells against TNBC tumor cell at E:T ratio of 5:1 for 3 days' co-culture.²

Anti-MUC1 CAR-T In Vivo Assays

Efficacy Test of Anti-MUC1 CAR-T

For in vivo tumor killing analysis, Creative Biolabs provides many optimized mouse models and various detection solutions to speed clients' CART research. At the same time, our in vivo services also cover a variety of phenotypic analyses on cells.

Fig.6 In vivo anti-tumor validation of MUC1 CAR-T cells against HCC70 tumor cells. (A) Anti-MUC1 CAR-T cells inhibit HCC70 tumor growth in NSG mice by a single injection in vivo. (B) Tumor weight analysis of resected tumor mass on day 57 at endpoint.²

Toxicity Evaluation Anti-MUC1 CAR-T

In addition, Creative Biolabs also provides comprehensive solutions for the toxicity assessment of CAR-T cells to ensure the safety and efficacy of the CART cells, such as on-target toxicity assessment, and off-target toxicity assessment.

For more MU1 CAR-T related assays, please don't hesitate to contact us directly.

References

1. Bose, Mukulika, and Pinku Mukherjee. "Potential of anti-MUC1 antibodies as a targeted therapy for gastrointestinal cancers." Vaccines 8.4 (2020): 659.
2. Zhou, Ru.; et al. "CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth." Frontiers in immunology 10 (2019): 1149.